NZ718802A - Icotinib-containing topical skin pharmaceutical composition and use thereof - Google Patents

Icotinib-containing topical skin pharmaceutical composition and use thereof

Info

Publication number
NZ718802A
NZ718802A NZ718802A NZ71880214A NZ718802A NZ 718802 A NZ718802 A NZ 718802A NZ 718802 A NZ718802 A NZ 718802A NZ 71880214 A NZ71880214 A NZ 71880214A NZ 718802 A NZ718802 A NZ 718802A
Authority
NZ
New Zealand
Prior art keywords
icotinib
topical
preparations
pharmaceutical composition
tyrosine kinase
Prior art date
Application number
NZ718802A
Other languages
English (en)
Inventor
Yinxiang Wang
Shujun Yuan
Yanping Wang
Shaojing Hu
Yunyan Hu
Original Assignee
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betta Pharmaceuticals Co Ltd filed Critical Betta Pharmaceuticals Co Ltd
Publication of NZ718802A publication Critical patent/NZ718802A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ718802A 2013-10-11 2014-10-11 Icotinib-containing topical skin pharmaceutical composition and use thereof NZ718802A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2013085042 2013-10-11
PCT/CN2014/088344 WO2015051763A1 (zh) 2013-10-11 2014-10-11 一种含埃克替尼的皮肤外用药物组合物及其应用

Publications (1)

Publication Number Publication Date
NZ718802A true NZ718802A (en) 2017-09-29

Family

ID=52812537

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ718802A NZ718802A (en) 2013-10-11 2014-10-11 Icotinib-containing topical skin pharmaceutical composition and use thereof

Country Status (13)

Country Link
US (2) US20160235757A1 (cg-RX-API-DMAC10.html)
EP (1) EP3056206A4 (cg-RX-API-DMAC10.html)
JP (1) JP6463745B2 (cg-RX-API-DMAC10.html)
AU (1) AU2014334222B2 (cg-RX-API-DMAC10.html)
BR (1) BR112016007627A2 (cg-RX-API-DMAC10.html)
CA (1) CA2926874C (cg-RX-API-DMAC10.html)
HK (1) HK1213813A1 (cg-RX-API-DMAC10.html)
IL (1) IL245015A0 (cg-RX-API-DMAC10.html)
NZ (1) NZ718802A (cg-RX-API-DMAC10.html)
RU (1) RU2698796C2 (cg-RX-API-DMAC10.html)
SG (1) SG11201602826VA (cg-RX-API-DMAC10.html)
TW (1) TWI630921B (cg-RX-API-DMAC10.html)
WO (1) WO2015051763A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014280710B2 (en) * 2013-06-09 2016-12-22 Betta Pharmaceuticals Co., Ltd New polymorphic forms of Icotinib phosphate and uses thereof
WO2022022434A1 (zh) * 2020-07-27 2022-02-03 杭州和正医药有限公司 含托法替尼药学上可接受的盐的药物组合物、制剂及应用
WO2022166794A1 (zh) * 2021-02-02 2022-08-11 贝达药业股份有限公司 埃克替尼在非小细胞肺癌术后辅助治疗中的应用
CN116492293A (zh) * 2022-01-25 2023-07-28 杭州和正医药有限公司 一种含托法替尼的局部用药的药物组合物、制剂及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007060116A2 (de) * 2005-11-24 2007-05-31 Basf Se Keratinbindende effektormoleküle und verfahren zu deren herstellung durch kopplung keratinbindender polypeptide mit carboxylgruppen oder sulfonsäuregruppen tragenden effektormolekülen
FR2909284B1 (fr) * 2006-11-30 2012-09-21 Galderma Sa Nouvelles compositions sous forme d'onguent sans vaseline comprenant un derive de vitamine d et eventuellement un anti-inflammatoire steroidien
KR20110031370A (ko) * 2008-07-08 2011-03-25 베타 파마, 인크. 염산 icotinib, 합성, 결정형, 약학적 조성물 및 이의 사용
GB201010954D0 (en) * 2010-06-29 2010-08-11 Edko Pazarlama Tanitim Ticaret Compositions
MX2013004296A (es) * 2010-10-21 2013-09-26 Cadila Healthcare Ltd Composiciones farmaceuticas topicas que contienen gotas de tamaño nanometrico para el tratamiento de soriasis.

Also Published As

Publication number Publication date
US20190321369A1 (en) 2019-10-24
CA2926874A1 (en) 2015-04-16
RU2698796C2 (ru) 2019-08-30
IL245015A0 (en) 2016-05-31
CA2926874C (en) 2018-12-11
SG11201602826VA (en) 2016-05-30
AU2014334222A1 (en) 2016-05-05
WO2015051763A1 (zh) 2015-04-16
EP3056206A4 (en) 2017-07-05
RU2016118063A (ru) 2017-11-16
HK1213813A1 (zh) 2016-07-15
TW201513894A (zh) 2015-04-16
TWI630921B (zh) 2018-08-01
AU2014334222B2 (en) 2017-03-09
US20160235757A1 (en) 2016-08-18
JP2016532659A (ja) 2016-10-20
EP3056206A1 (en) 2016-08-17
BR112016007627A2 (pt) 2017-08-01
JP6463745B2 (ja) 2019-02-06

Similar Documents

Publication Publication Date Title
MX391180B (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo
BR112016000561B8 (pt) Compostos terapeuticamente ativos, uso dos mesmos, composição farmacêutica e uso da mesma
MX373042B (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
MX2015010185A (es) Composicion para uso cosmetico adecuada para producir un efecto de pigmentacion sobre el cabello.
MX2016009666A (es) Suministro topico de composiciones para la piel que tienen ph bajo.
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
HK1207069A1 (en) Heterocyclic compounds and uses thereof
MX2021013139A (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
RU2018135973A (ru) Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака
PH12016502353A1 (en) Pharmaceutical composition
NZ711500A (en) Engineering a control drug release profile via liposome compositions in both aqueous and non-aqueous compartments
BR112013024824A2 (pt) ésteres isopentílicos para uso em composições cosméticas, dermatológicas ou farmacêuticas
EA201690077A1 (ru) Терапевтически активные производные эстратриен-тиазола
SA519410993B1 (ar) النشاط المضاد للبكتيريا لأوليجو سكاريد من جالاكتو وزيليتول في العلاجات الجلدية
BR112015027436A2 (en) Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients
MX2016001422A (es) Composicion farmaceutica de fingolimod.
MX379253B (es) Formulaciones de oximetazolina estabilizadas y sus usos.
BR112016007627A2 (pt) composições farmacêuticas tópicas para a pele contendo icotinib e utilizações das mesmas
MX391191B (es) Composiciones de liberación extendida de onapristona y métodos.
SA516370446B1 (ar) تركيبة صيدلانية مستقرة مضادة للدرن في صورة قرص قابل للتشتت يحتوي على حبيبات إيزونيازيد وحبيبات ريفابنتين، وعملية لتحضيرها
BR112013026933A2 (pt) uso de uma combinação de pelo menos um carotenoide
PH12016500120A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
MX2015014905A (es) Compuestos de pirazino - [1,2-a] indol, su preparacion y su uso en medicamentos.
PH12015502420A1 (en) PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 OCT 2019 BY ACUMASS

Effective date: 20180918

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 OCT 2020 BY ACUMASS

Effective date: 20190917

LAPS Patent lapsed